Celldex Therapeutics (CLDX) SVP Cavanaugh Buys 95,000 Shares

Sarah Cavanaugh Purchases Celldex Therapeutics Stock

Sarah Cavanaugh, Senior Vice President of Corporate Affairs and Administration at Celldex Therapeutics, Inc. (NasdaqCM: CLDX), acquired 95,000 shares of the biotechnology company on June 25, 2026. This transaction formed part of a coordinated wave of stock purchases by top leadership at the firm on that date.

Broad Insider Buying Push at Celldex Therapeutics

The purchase by Cavanaugh aligned with multiple insider transactions executed on June 25, 2026. CEO Anthony Marucci acquired 375,000 shares, while Executive VP and CSO Tibor Keler picked up 115,000 shares. Additional buyers included SVP and General Counsel Freddy Jimenez with 93,000 shares, SVP of Regulatory Affairs Margo Heath-Chiozzi with 95,000 shares, and directors Harry Penner Jr. and Herbert Conrad, who each bought 26,000 shares.

Celldex Stock Performance

On Tuesday, shares of Celldex changed hands around $37.44. The stock has traded between a 52-week low of $22.10 and a high of $45.14. It currently sits above its 200-day moving average of $32.18 and near its 50-day moving average of $39.10. The biotechnology firm has a market capitalization of roughly $2.98 billion and does not have a meaningful forward P/E ratio due to negative earnings.

Analysts Set New Price Targets

Wall Street firms have remained active with their views on Celldex. On October 2, 2026, HC Wainwright & Co. reiterated its buy rating with a $64.00 price target. Earlier in September, Leerink Partners maintained an outperform rating while lifting its target to $88.00 from $70.00, and Morgan Stanley maintained an overweight rating while raising its target to $57.00 from $50.00. Across 14 analyst opinions, the stock holds a consensus recommendation of strong buy and a mean price target of $59.07.

About Celldex Therapeutics

Celldex Therapeutics is a biopharmaceutical company based in Hampton, New Jersey, focused on developing targeted therapeutic antibodies for severe inflammatory, allergic, and autoimmune diseases. Its clinical pipeline features drug candidates designed to address mast cell-mediated conditions where current treatment options remain limited.

What to Watch Next for Celldex

Investors are monitoring upcoming regulatory updates from the company's inflammatory disease programs as well as its next financial results, scheduled for release on November 9, 2026. Insider transactions remain a matter of public record reported via SEC filings and reflect individual leadership decisions rather than an indicator of short-term price direction.